Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion

March 25, 2026 updated by: Hasnain Ali, Shifa International Hospital

Total knee arthroplasty is a common operation performed to relieve pain and improve movement in patients with severe knee joint disease, such as osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, or osteonecrosis. However, blood loss after surgery remains an important concern because it may lead to a fall in hemoglobin level and increase the need for blood transfusion. Blood transfusion may be necessary in some patients, but it also carries additional risks and cost. One practice that may influence postoperative blood loss is the use of a surgical drain. A drain is commonly placed at the end of surgery to remove blood and fluid from the operated area, but its benefit in total knee arthroplasty remains uncertain. Some studies suggest that drains may reduce blood collection inside the joint, whereas others suggest that they may increase overall blood loss by preventing the natural pressure effect that helps stop bleeding.

This randomized clinical trial is being conducted to compare hemoglobin drop and blood transfusion requirement in patients undergoing primary unilateral total knee arthroplasty with or without drain insertion. A total of 102 patients will be enrolled and randomly allocated into two equal groups. In Group A, a closed suction drain will be inserted at the end of surgery. In Group B, no drain will be used. All operations will be performed using a standardized surgical technique, and all patients will receive similar perioperative care, including tranexamic acid, analgesia, thromboprophylaxis, and rehabilitation.

Hemoglobin levels will be measured before surgery and again at 24 and 48 hours after surgery. The main outcomes will be the amount of hemoglobin drop after surgery and whether blood transfusion is required. Blood transfusion will be given according to the predefined hospital protocol when hemoglobin falls below 8 g/dL. The study hypothesis is that there is a significant difference in postoperative hemoglobin drop and blood transfusion requirement between patients undergoing primary knee arthroplasty with drain insertion and those undergoing surgery without drain insertion.

Study Overview

Study Type

Interventional

Enrollment (Actual)

102

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Fedral
      • Islamabad, Fedral, Pakistan, 44000
        • Shifa International Hospital, Islamabad

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 50 and 80 years.
  • Both male and female patients.
  • Diagnosed with:
  • Primary knee osteoarthritis.
  • Rheumatoid arthritis.
  • Arthritis following trauma.
  • Osteonecrosis, or avascular necrosis.
  • Unilateral primary total knee arthroplasty (TKA) is necessary due to severe knee pain, stiffness, and non-responsiveness to conservative treatment.
  • Patients with a Knee Society Score (KSS) of ≤60 are considered to have functional limitations, which are characterized as a severe impairment in activities of daily living (ADLs) related to knee disease.
  • Preoperative hemoglobin ≥10 g/dL to ensure comparable baseline hemoglobin levels across groups.
  • BMI between 18.5 and 35 kg/m² to exclude extremes of underweight or morbid obesity.

Exclusion Criteria:

  • Patients undergoing revision TKA due to implant failure, infection, or periprosthetic fractures.
  • Individuals with aberrant coagulation parameters (INR >1.5, extended PT/aPTT) or inherited or acquired bleeding diseases (such as hemophilia or von Willebrand disease).
  • Patients receiving antiplatelet therapy (ticagrelor, clopidogrel) or long-term anticoagulants (warfarin, DOACs) within seven days of surgery.
  • Individuals with sickle cell disease, thalassemia, or chronic anemia (Hb <10 g/dL).
  • Individuals with severe COPD, pulmonary hypertension, NYHA Class III or IV heart failure, or a history of DVT/PE within the last six months.
  • Severe chronic kidney disease (CKD) stage 4/5 (eGFR <30 mL/min/1.73m²) or severe hepatic dysfunction (Child-Pugh Class C, AST/ALT >3×normal, bilirubin >2 mg/dL).
  • Patients with active systemic infections (sepsis, tuberculosis, HIV/AIDS, hepatitis B/C, osteomyelitis).
  • Patients with a history of thromboembolic events (DVT/PE/stroke within 12 months) or contraindications to tranexamic acid (TXA).
  • Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A (Drain Insertion Group)
Patients undergoing primary unilateral total knee arthroplasty with placement of a closed suction drain at the end of surgery.
A closed suction drain will be placed at the surgical site at the end of primary total knee arthroplasty to allow postoperative drainage of blood and fluid.
Other: Group B (Non-Drain Group)
Patients undergoing primary unilateral total knee arthroplasty without placement of a drain.
Primary total knee arthroplasty will be performed without insertion of a postoperative surgical drain. Standard perioperative management, including tranexamic acid, analgesia, thromboprophylaxis, and rehabilitation, will be provided similarly to the drain group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative hemoglobin drop at 24 hours
Time Frame: 24 hours after surgery
Hemoglobin drop will be calculated as the difference between preoperative hemoglobin measured within 24 hours before surgery and postoperative hemoglobin measured 24 hours after primary total knee arthroplasty. Hemoglobin will be measured in g/dL using a standardized laboratory assay.
24 hours after surgery
Postoperative hemoglobin drop at 48 hours
Time Frame: 48 hours after surgery
Hemoglobin drop will be calculated as the difference between preoperative hemoglobin measured within 24 hours before surgery and postoperative hemoglobin measured 48 hours after primary total knee arthroplasty. Hemoglobin will be measured in g/dL using a standardized laboratory assay.
48 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hasnain Ali, Shifa International Hospital, Islamabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2025

Primary Completion (Actual)

January 31, 2026

Study Completion (Actual)

January 31, 2026

Study Registration Dates

First Submitted

March 20, 2026

First Submitted That Met QC Criteria

March 20, 2026

First Posted (Actual)

March 27, 2026

Study Record Updates

Last Update Posted (Actual)

March 30, 2026

Last Update Submitted That Met QC Criteria

March 25, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Closed Suction Drain Insertion

Subscribe